.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma layer, taking up the leading science spot at Sanofi.Quigley is going to begin Sept. 30 as the French Big Pharma's main scientific policeman and worldwide head of research study, Sanofi informed Tough Biotech in an emailed declaration.Quigley is changing Frank Nestle, M.D., who left behind Sanofi this spring among a global overhaul of the company's R&D system. Nestle, who devoted 8 years with the pharma, leapt over to Deerfield Control, where he currently acts as a companion on the therapeutics team and also chief executive officer of the agency's curative exploration and also growth procedures.
Quigley will certainly participate in Sanofi from a San Francisco-based biotech that remains in secrecy, according to his LinkedIn profile. He's presently specified as the provider's co-founder, president and also CEO.Because August 2021, Quigley has actually acted as an endeavor companion at SV Health Investors, a medical care fund supervisor with existing investments in biotechs like BioAge, Cerevance, Dualitas Therapeutics and Nimbus Therapies, among others. Quigley formerly stored the leading area at Dualitas, a biotech that stays in secrecy, depending on to STAT.The future Sanofi forerunner also previously helmed Therini Bio, an immunotherapy biotech operating to create procedures for neurodegenerative health conditions steered by vascular dysfunction.Prior to devoting the final few years in biotech, Quigley has an also longer record in Big Pharma, very most just recently working as Gilead's elderly bad habit head of state of study biology up until the summertime of 2021. Prior to that, he clocked in greater than 4 years across different management duties at Bristol Myers Squibb and also functioned as a medical supervisor at Johnson & Johnson's Janssen arm prior to that.Sanofi claimed Quigley's goal in his new role will be to "optimize our likelihood of effectiveness via optimum collaborations across our institution and past, taking best-in-class development in addition to building as well as sourcing brand new industry-leading skill with a dedication to diversity," depending on to an inner memo obtained by STAT.